Kyorin expects $10 million sales after Flutiform launch in Japan for asthma

19 November 2013

UK drug delivery specialist Skyepharma (LSE: SKP) has announced that Flutiform (fluticasone propionate/formoterol fumarate) has been launched in Japan following a pricing reimbursement agreement.

Flutiform is marketed in Japan by Skyepharma’s licensing partner, Kyorin Pharmaceutical (TYO: 4569), as Flutiform 50 Aerosol and Flutiform 125 Aerosol (both 56 inhalations) for the treatment of patients aged 16 years and over with bronchial asthma. A milestone of several million US dollars was received from Kyorin following regulatory approval in July and Skyepharma is entitled to high-mid single digit royalties on net sales. UK market analysts N+1 Singer stated: “Since our Healthcare & Life Sciences sector report ‘Dealing with the New Normal’ in April 2013 the share price has rallied 158%. We believe Skyepharma has the ability to generate significant growth in the future.”

Pricing reimbursement

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK